A national questionnaire survey of Japanese urologists on treatment perspectives for elderly prostate cancer patients.
elderly patients
prostate cancer
questionnaire survey
treatment perspective
urologists
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
12
12
2022
accepted:
27
04
2023
medline:
2
8
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
This study conducted a national questionnaire survey of Japanese urologists from a treatment perspective for older patients with prostate cancer. A questionnaire was distributed to 922 teaching hospitals of the Japanese Urological Association. Questionnaire items included years of urologist experience, gender, workplace, treatment equipment owned, daily specialty practice area, urological cancer specialty, treatment reference items for older adults, upper age limit for radical treatment, medication, and two hypothetical cases of Gleason grade group 2 prostate cancer with or without oligometastasis. In total, 1732 questionnaires were analyzed, with responses evenly distributed across all age groups. Workplaces included general hospitals (49.4%), university hospitals (40.3%), and cancer centers (4.2%). Performance status was the most frequently mentioned treatment-related item, followed by comorbidities and cognitive function. In addition, geriatric assessment was used by only 13.3% of respondents. No upper age limit was found for total prostatectomy, brachytherapy, and external beam radiation. Anti-androgens, androgen receptor-axis-targeted agents, chemotherapy, poly ADP ribose polymerase inhibitors, and immune-checkpoint inhibitors were selected by 6.8%, 35.6%, 47.3%, 89%, 62.8%, 24.7%, 41.9%, and 41.7% of the respondents, respectively. Response rates for administration of hormone therapy for hypothetical cases of Gleason grade group 2 prostate cancer with or without oligometastases were 96.8% and 61.2%, respectively. Less than 15% of urologists used geriatric assessments. Several responded that they would set age limits for highly invasive radical and systemic therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
672-680Informations de copyright
© 2023 The Japanese Urological Association.
Références
National Cancer Registry MoH, Labour and Welfare. Cancer Statistics. Cancer Information Service, National Cancer Center. 2023. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html
Ariane MM, Ploussard G, Rebillard X, Malavaud B, Rischmann P, Hennequin C, et al. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey. World J Urol. 2015;33:1741-7.
Wenzler DL, Rosenberg BH. Urologists' personal feelings on PSA screening and prostate cancer treatment. J Eval Clin Pract. 2014;20:408-10.
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25:524-31.
Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116-36.
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595-603.
Mohile SG, Epstein RM, Hurria A, Heckler CE, Canin B, Culakova E, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community oncology research program. JAMA Oncol. 2020;6:196-204.
Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology. 2001;58:977-82.
Houterman S, Janssen-Heijnen ML, Hendrikx AJ, van den Berg HA, Coebergh JW. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol Hematol. 2006;58:60-7.
Aas K, Dorothea Fossa S, Age Myklebust T, Møller B, Kvåle R, Vlatkovic L, et al. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. Cancer Med. 2020;9:6646-57.
Network NCC. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, version 1.2023. 2023.
Ministry of Health Law, Japan. 23th Life Table. 2022.
Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, et al., editors. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194:1277-84.
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27:286-94.
Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014;65:875-83.
Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014;25:429-34.
Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, de Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5:119-26.
Matsubara N, Suzuki K, Kazama H, Tsukube S, Seto T, Matsuyama H. Cabazitaxel in patients aged >/=80years with castration-resistant prostate cancer: results of a post-marketing surveillance study in Japan. J Geriatr Oncol. 2020;11:1067-73.
Suzuki K, Grillo V, Chen Y, Singh S, Ledesma DA. Understanding treatment strategies and preferences in nonmetastatic castration-resistant prostate cancer from the Japanese physician perspective. JCO Glob Oncol. 2021;7:302-10.
Uemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urol. 2016;16:63.
Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev. 2017;9:CD009625.
Popiolek M, Rider JR, Andrén O, Andersson SO, Holmberg L, Adami HO, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63:428-35.
Center for Cancer Control and Information Services NCC. Monitoring of Cancer Incidence in Japan-Survival 2009-2011 report. 2020.